Recent ucsdsom_biomarkerssymposium_2024 items

Cardiac magnetic resonance imaging paralleled recurrent pericarditis clinical response to rilonacept treatment over 18 months: a RHAPSODY subgroup analysis

Tue, 12 May 2026 00:00:00 +0000

Cardiac magnetic resonance imaging paralleled recurrent pericarditis clinical response to rilonacept treatment over 18 months: a RHAPSODY subgroup analysis

Authors:

Paul C. Cremer, MD¹, Antonio Brucato, MD², Antonella Insalaco, MD³, David Lin, MD⁴, Sushil A. Luis, MBBS, PhD⁵, Deborah H. Kwon, MD¹, Christine L. Jellis, MD, PhD¹, JoAnn Clair, PhD, MBA⁶, Allison Curtis, PhD⁶, Sheldon Wang, PhD⁶, Allan L. Klein, MD¹, Massimo Imazio, MD⁷, John F. Paolini,MD, PhD⁶, for the RHAPSODY investigators.

¹Department of Cardiovascular Imaging, Center for the Diagnosis and Treatment of Pericardial Diseases, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio, USA;

²Department of Biomedical and Clinical Science, University...

A Case of Olanzapine-Induced Dyslipidemia

Tue, 12 May 2026 00:00:00 +0000

A Case of Olanzapine-Induced Dyslipidemia

Andrew S. Kao MD¹, Harpreet S. Bhatia MD, MAS²

¹Department of Medicine, UC San Diego Health, La Jolla, CA, USA

²Division of Cardiovascular Medicine, UC San Diego Health, La Jolla, CA, USA

Introduction: Elevation in lipid biomarkers, specifically total cholesterol (TC), LDL-C, and triglyceride levels, can be observed within 4 weeks of initiation of atypical anti-psychotic medications without significant HDL-C alteration. Olanzapine use is associated with a five-fold risk increase in risk of developing dyslipidemia and higher predisposition to an ASCVD event. Routine assessment of lipid profile is crucial to minimize cardiovascular risk among patients with psychiatric comorbidities in need of long-term anti-psychotics.

Case: A 51-year-old woman with history of breast cancer on adjuvant...

Serial Lipoprotein(a) Measurements in Heart Transplant Recipients

Tue, 12 May 2026 00:00:00 +0000

Serial Lipoprotein(a) Measurements in Heart Transplant Recipients

Andrew S. Kao MD¹, Antoinette Birs MD², Jose Cruz Rodriguez MD²

¹Department of Medicine, UC San Diego Health, La Jolla, CA, USA

²Division of Cardiovascular Medicine, UC San Diego Health, La Jolla, CA, USA

Introduction: Lipoprotein (a), a genetically determined lipid carrier molecule consists of low-density lipoprotein with apolipoprotein B-100 and apolipoprotein (a), is a well-established biomarker with casual association to development of atherosclerotic cardiovascular disease (ASCVD) events.¹ ACC/AHA guidelines recommend lipid lowering therapy for Lp(a) level >50 mg/dL,² as Lp(a) has a positive association with intima thickening leading to coronary allograft vasculopathy (CAV).^3-4 The following case demonstrates the utility in serial Lp(a)...